Abstract: A soft gelatin capsule with a filling including lysine clonixinate as an active ingredient and in a hydrophilic matrix and with a shell comprising gelatin, a plasticizer and sorbitol, wherein the plasticizer in many instances will be glycerol but may comprise the sorbitol alone. The presence of sorbitol in the gelatin capsule of a lysine clonixinate dosage form imparts unexpectedly good drug release and stability thereto.

Abstract: Substituted N-aminoalkylmethane sulfanilide of formula (I), their solutions and pharmaceutically acceptable addition salts, their pharmaceutical compositions and their therapeutic use. In formula (I) Y represents hydrogen, cyano, nitro, amino, acetamide or halogen; n is an integer between 2 and 4, R.sup.1 and R.sup.2 equal or different are alkyl-(C1-C4) or they are connected together and with the N-atom thereby forming a 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-methyl-1-piperazinyl, 4-ethylpiperazinyl, 4-propylpiperazinyl, 1-homopiperidinyl or 4-morpholine residue. The products of formula (I) are used as antispasmodic agents.

Abstract: The present invention concerns compounds of formula (I) which is the novel 2-(1-pyrrolidinyl)ethylester of (.+-.)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxyl- or ketorolac-acid, the pharmaceutically acceptable addition salts thereof, preferably oxalate. It is known that the commercially available ketorolac (trometamole salt) exhibits undesired side effects (gastrointestinal irritation and ulceration). Surprisingly, when applying the compounds according to the invention there are considerably less undesired effects which render them potentially of great advantage as analgetic/antiphlogistic agent.

Abstract: The present invention concerns compounds of formula (I) which is the novel 2-(1-pyrrolidinyl)ethylester of (.+-.)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxyl- or ketorolac-acid, the pharmaceutically acceptable addition salts thereof, preferably oxalate. It is known that the commercially available ketorolac (trometamole salt) exhibits undesired side effects (gastro-intestinal irritation and ulceration). Surprisingly, when applying the compounds according to the invention there are considerably less undesired effects which render them potentially of great advantage as analgetic/antiphlogistic agent.

Abstract: Pharmaceutical preparations containing 1 to 10% by weight L-lysine salt of the 2-[(3-chloro-2-methylphenyl)amino]-3-pyridine carboxylic acid as active substance, 2 to 15% by weight pharmaceutically acceptable emulsifiers, 2 to 20% by weight pharmaceutically acceptable emollients, 0.01 to 0.2% by weight pharmaceutically acceptable preservation substances and the remainder water made up to 100% by weight, and possibly 0.2 to 5% by weight rubefacients, the water being correspondingly adjusted to a total of 100% by weight, are suitable for topical application to relieve/alleviate pain and/or inflammation in humans and animals.